JP6073888B2 - トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法 - Google Patents

トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法 Download PDF

Info

Publication number
JP6073888B2
JP6073888B2 JP2014526189A JP2014526189A JP6073888B2 JP 6073888 B2 JP6073888 B2 JP 6073888B2 JP 2014526189 A JP2014526189 A JP 2014526189A JP 2014526189 A JP2014526189 A JP 2014526189A JP 6073888 B2 JP6073888 B2 JP 6073888B2
Authority
JP
Japan
Prior art keywords
tumstatin
transferrin
protein
recombinant protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014526189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526890A (ja
JP2014526890A5 (enExample
Inventor
ビー． コンペラ，ウダイ
ビー． コンペラ，ウダイ
アイ． シャインマン，ロバート
アイ． シャインマン，ロバート
ティアギ，プニート
Original Assignee
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート, ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート filed Critical ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
Publication of JP2014526890A publication Critical patent/JP2014526890A/ja
Publication of JP2014526890A5 publication Critical patent/JP2014526890A5/ja
Application granted granted Critical
Publication of JP6073888B2 publication Critical patent/JP6073888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014526189A 2011-08-17 2012-08-15 トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法 Active JP6073888B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524508P 2011-08-17 2011-08-17
US61/524,508 2011-08-17
PCT/US2012/051013 WO2013025846A2 (en) 2011-08-17 2012-08-15 Transferrin-tumstatin fusion protein and methods for producing and using the same

Publications (3)

Publication Number Publication Date
JP2014526890A JP2014526890A (ja) 2014-10-09
JP2014526890A5 JP2014526890A5 (enExample) 2015-08-27
JP6073888B2 true JP6073888B2 (ja) 2017-02-01

Family

ID=47715692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526189A Active JP6073888B2 (ja) 2011-08-17 2012-08-15 トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法

Country Status (15)

Country Link
US (1) US9290562B2 (enExample)
EP (1) EP2744831B1 (enExample)
JP (1) JP6073888B2 (enExample)
CN (2) CN110105453A (enExample)
AU (1) AU2012296588B2 (enExample)
BR (1) BR112014008680A2 (enExample)
CA (1) CA2849015C (enExample)
DK (1) DK2744831T3 (enExample)
ES (1) ES2659161T3 (enExample)
NO (1) NO2820418T3 (enExample)
PL (1) PL2744831T3 (enExample)
PT (1) PT2744831T (enExample)
SI (1) SI2744831T1 (enExample)
TR (1) TR201802686T4 (enExample)
WO (1) WO2013025846A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995626B1 (en) * 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
EP3010525A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR101818151B1 (ko) 2016-03-25 2018-01-16 한국과학기술원 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US20050192242A1 (en) 1995-10-11 2005-09-01 Neal Zane C. Therapeutic fusion protein transgenes
KR100682666B1 (ko) * 1998-06-17 2007-02-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 항혈관형성 단백질 및 이들을 사용하는 방법
EP1244701A1 (en) 1999-12-23 2002-10-02 Human Genome Sciences, Inc. Transferrin polynucleotides, polypeptides, and antibodies
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
EP1670428A4 (en) 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
EP1812030A4 (en) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
AU2007211846B2 (en) 2006-02-03 2013-05-23 The University Of Sydney A method of modulating cellular activity and agents for use therein
CN101070349B (zh) * 2007-05-22 2010-10-13 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs

Also Published As

Publication number Publication date
AU2012296588A1 (en) 2014-04-03
CA2849015C (en) 2017-08-08
BR112014008680A2 (pt) 2017-06-13
JP2014526890A (ja) 2014-10-09
CN103998470A (zh) 2014-08-20
EP2744831A2 (en) 2014-06-25
SI2744831T1 (en) 2018-04-30
DK2744831T3 (en) 2018-03-05
US9290562B2 (en) 2016-03-22
WO2013025846A2 (en) 2013-02-21
AU2012296588B2 (en) 2017-07-27
CN110105453A (zh) 2019-08-09
WO2013025846A3 (en) 2013-05-02
EP2744831B1 (en) 2017-12-06
CA2849015A1 (en) 2013-02-21
PT2744831T (pt) 2018-03-05
TR201802686T4 (tr) 2018-03-21
ES2659161T3 (es) 2018-03-14
NO2820418T3 (enExample) 2018-05-05
US20140179612A1 (en) 2014-06-26
EP2744831A4 (en) 2015-03-11
PL2744831T3 (pl) 2018-05-30

Similar Documents

Publication Publication Date Title
Liu et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery
JP6073888B2 (ja) トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法
Amaral et al. Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
JP2019123711A (ja) Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法
CN108348572B (zh) 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
CN110036024B (zh) 肌肉性能改善化合物
US20220265843A1 (en) Extracellular vesicle-mediated delivery to cells
Johnen et al. Antiangiogenic and Neurogenic Activities of Sleeping Beauty‐Mediated PEDF‐Transfected RPE Cells In Vitro and In Vivo
Darche et al. Antagonist of nucleolin, N6L, inhibits neovascularization in mouse models of retinopathies
Kumar et al. Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues
Puranen et al. Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice
CN112274631B (zh) 重组蛋白Semaphorin3G在防治视网膜疾病中的医药用途
JP2018515586A (ja) 骨減少症および骨粗鬆症の治療におけるＢ７ｈ受容体のリガンド
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
Talreja et al. G-quartet oligonucleotide mediated delivery of functional X-linked inhibitor of apoptosis protein into retinal cells following intravitreal injection
JP5756024B2 (ja) Ｏｔｘ２標的細胞を特異的にターゲティングするためのポリペプチド
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
KR20220147787A (ko) 보체 경로 억제 단백질을 포함하는 융합단백질 및 이의 용도
Piroozmand et al. MiRGD peptideticle targeted delivery of hinge-truncated soluble VEGF receptor 1 fusion protein to the retinal pigment epithelium cell line and newborn mice retina
Yan et al. Construction of a plasmid for human brain-derived neurotrophic factor and its effect on retinal pigment epithelial cell viability
Khazaei et al. Development of a cell permeable competitive antagonist of RhoA and CRMP4 binding, TAT-C4RIP, to promote neurite outgrowth
Gounari et al. Research Article Intravitreal Administration Effect of Adipose-Derived Mesenchymal Stromal Cells Combined with Anti-VEGF Nanocarriers, in a Pharmaceutically Induced Animal Model of Retinal Vein Occlusion
EP3096769A1 (en) Therapeutic use of vegfr-3 ligands
Kumar-singh Platform for Rapid Delivery of Biologics and Drugs to Ocular Cells and Tissues Following Combat Associated Trauma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170105

R150 Certificate of patent or registration of utility model

Ref document number: 6073888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250